Thus, it was suggested more than a decade ago (Fuxe et al., 2008) and recently demonstrated (Borroto-Escuela et al., 2020; Valle-León et al., 2020) that drugs promoting A2AR-D2R heteromer formation might constitute an alternative strategy for the treatment of schizophrenia. This evidence concerns the gene DRD2 and schizophrenia.